Mutation Load Offers Biomarker in SCLC.
Tumor mutation burden offers a promising predictive biomarker for patients with small cell lung cancer. An exploratory analysis presented at the World Conference on Lung Cancer showed that the patients with large numbers of mutations in their cancer cells were more likely to respond-and for a longer time-to a single checkpoint inhibitor or a combination of them than those with a low mutation load.